Live attenuated *Salmonella* displaying HIV-1 10E8 epitope on fimbriae: systemic and mucosal immune responses in BALB/c mice by mucosal administration

Qing-Hai Li¹, Gang Jin¹,*, Jia-Ye Wang², Hai-Ning Li³, Huidi Liu¹, Xiao-Yun Chang¹, Fu-Xiang Wang⁴ & Shu-Lin Liu¹,⁵

The HIV-1 membrane proximal external region (MPER) that is targeted by several broadly neutralizing antibodies (BNAbs) has been considered a potential immunogen for vaccine development. However, to date the immunogenicity of these BNAB epitopes has not been made sufficiently adequate. In the present work, we used live attenuated *Salmonella* as a platform to present the HIV-1 MPER 10E8 epitope in the fimbriae. The insertion of the 10E8 epitope into the fimbriae had no significant influence on the expression and the absorption capacity of bacterial fimbriae, nor on the virulence and invasiveness of the attenuated *Salmonella*. After oral administration of the vaccine construct to mice followed by 10E8 epitope peptide boost, specific antibody responses in serum and mucosa as well as memory lymphocytes in spleen and plasma cells in bone marrow were induced. We also found that the live attenuated *Salmonella* vector directed the immunity toward Th1 bias, induced Th1 and Th2 cytokine responses and stimulated significant B cell differentiation into GC B, memory B and plasma cells. Therefore, we propose that the live attenuated *Salmonella* constitutively expressing HIV-1 BNAb epitopes on the fimbriae will be an effective approach to improving immune microenvironment and enhancing the immunogenicity of HIV-1 epitope vaccines.

Developing effective vaccines against human immunodeficiency virus type 1 (HIV-1) still faces considerable challenges three decades after the discovery of the virus¹². Enormous and persistent efforts have been made to generate many vaccine candidates, including the vaccine in trial RV144 that showed modest protection³⁴, but so far none has shown the effects useful for human vaccination. Recent studies on HIV-1 pathogenesis and vaccinology have given rise to a general consensus for vaccine design that an ideal HIV-1 vaccine paradigm should simulate the natural route of viral infection⁵–⁷. Since the primary site of HIV-1 infection is the mucosal surface⁸, the elicitation of protective antibody (neutralizing or non-neutralizing antibody) responses not only in systemic but also in mucosal compartments should be taken into consideration for HIV-1 vaccine design.

Most naturally infected individuals develop strain-specific antibodies against HIV-1; of interest, approximately 5–25% of HIV-1 infected individuals may develop broadly neutralizing antibodies (BNAbs), which is the primary goal for prophylactic HIV-1 vaccines¹⁰–¹². Since 2009, a growing number of BNAbs have been reported, with most showing wide breadth and strong potency¹³,¹⁴. The targets of such antibodies on the HIV-1 envelope glycoprotein (Env) can be grouped into three parts: gp120, gp41 and the interface region of gp120-gp41¹³,¹⁵. Thus, epitopes identified in these regions have been chosen as immunogens for HIV-1 vaccine designs. Among

¹Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin Medical University, Harbin, China. ²Department of Microbiology, Harbin Medical University, Harbin, China. ³Department of Infectious Diseases, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China. ⁴Department of Infectious Diseases, The First Affiliated Hospital, Harbin Medical University, Harbin, China. ⁵Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, Canada. ⁶These authors contributed equally to this work. Correspondence and requests for materials should be addressed to F.-X.W. (email: wangfuxiang999@hotmail.com) or S.-L.L. (email: slliu@ucalgary.ca)
them, the membrane proximal external region (MPER) of gp41 subunit has been known as one of the most highly conserved sequences, contributing to the HIV-1 viral fusion and infectivity, and the epitopes of all three well-characterized BNAbs, 2F5, 4E10, and 10E8, are in MPER. Unfortunately, although these epitopes seem to be ideal for vaccine development due to their particularly suitable features such as being highly conserved, linear and easily accessible to immune molecules, many MPER-based vaccine strategies incorporating these epitopes in different conformations have resulted in merely weak or no epitope-specific neutralizing antibody responses in vivo. The main problem has been in the presentation manner of the epitopes to maximally preserve their high immunogenicity and some other natural features. Diverse approaches have been tried for this, including the scaffold protein method, nanoparticle techniques, and virus-like particle strategies. However, all these approaches have only slightly improved the immunogenicity of the MPRE epitopes, mainly because of the very limited numbers of antigenic epitopes to be displayed on the surface and short retention time of the vaccine vectors, which leads to inadequate stimulation to the immune system.

Recombinant bacterial vectors such as live attenuated Salmonella seem to be a solution, due to their ability to invade and colonize tissues after mucosal delivery. Upon infection and invasion of the intestinal mucosa, the Salmonella bacteria are taken up by macrophages or other antigen-presenting cells and will then grow inside these cells. Such features can allow for persistent exposure of vaccinated individuals to heterologous immunogens. Additionally, Salmonella infection will at the same time stimulate innate immunity, such as the activation of macrophages and the recruitment of other immune cells. In light of such advantages, Salmonella may be used as an ideal vector for the development of HIV-1 vaccines.

The MPER epitopes are hydrophobic components of the HIV-1 envelope glycoprotein, so the epitope peptide should be presented on the outer membrane component of the bacterial vectors in the vaccine to be developed. The Salmonella thin aggregative fimbriae can precisely satisfy this requirement compared to other strategies that have been described to date. In this study, we constructed live attenuated Salmonella that constitutively express the HIV-1 10E8 epitope on the thin aggregative fimbriae. After confirming the successful construction, we immunized mice by using different vaccination regimens and found that the recombinant vaccine Salmonella strain induced high levels of humoral and mucosal epitope-specific Ab responses and high frequency of B cells and plasma cells secreting antibodies specific to HIV-1.

**Results**

**Characterization of recombinant attenuated Salmonella expressing HIV-1 10E8 epitope.** We employed the scarless and efficient gene replacement system, using the temperature-sensitive plasmid pHSG415 as a carrier of foreign genes, to integrate the DNA fragment encoding the HIV-1 10E8 linear epitope into the fimbrin gene agfA of attenuated Salmonella typhimurium, ST-14028 3b aroA− (referred to as ST hereafter). DNA sequencing confirmed that recombinant S. typhimurium (ST-10E8) contained chimeric agfA:10E8 gene. To verify the expression of the chimeric fimbrial protein, we detected the AgfA and 10E8 by western blotting analysis and found that both AgfA protein and 10E8 epitope were present on the recombinant ST-10E8 strain (Fig. 1a).

**ST-10E8 showed comparable Congo red binding activity to ST.** To assess the intactness of the aggressive fimbriae that have the 10E8 epitope inserted, we conducted CR binding assay by using the hydrophobic Congo red dye (CR), the binding activity of which to Salmonella is commensurate with the amounts of aggressive fimbriae, and found that the CR bound by ST-10E8 was similar to that by ST. As expected, significantly less CR was bound by the AgfA-deficient ST (ST-ΔAgfA) (Fig. 1b).

**ST-10E8 showed comparable virulence and invasion ability to those of ST.** Considering that fimbriae contribute to the primary tissue attachment process of Salmonella, we wanted to know whether the modified fimbriae could influence the virulence such as invasiveness of ST. We infected the BALB/c mice (8–10 week old) orally with ST or ST-10E8 at doses from 107 to 1011 colony forming units (CFU) and found that these two groups had comparable survival rates at the same dose over a 4-week period (Fig. 1c,d). The 50% lethal doses (LD50) of ST and ST-10E8 in BALB/c mice were determined as 5.0 × 109 CFU and 6.3 × 109 CFU, respectively.

After infection with 1 × 109 CFU of ST-10E8 or ST, similar bacterial colonization status of these STs in lymphoid tissues was observed. Bacterial colonization in spleens was much heavier than that in Peyer's patches at the same time points. The bacterial loads of ST-10E8 were rapidly decreased from 3.4 × 109 CFU in spleen and 1.1 × 109 CFU in Peyer's patches at day 3 to 8.0 × 103 CFU and 4.8 × 104 CFU at day 9, respectively. Since then, bacterial loads were maintained at a low level and most of the bacteria were cleared out at day 30 after infection (Fig. 1e,f).

Together, these results indicated that the attenuated Salmonella ST-10E8 could display the HIV-1 10E8 epitope on functional aggressive fimbrial AgfA protein. Of special importance, the insertion of the foreign 10E8 epitope into the fimbriae had no significant influence on the expression of AgfA protein, the absorption capacity of bacterial fimbriae, or virulence such as the invasiveness of the attenuated Salmonella ST.

**Oral immunization with ST-10E8 induced 10E8 epitope specific systemic and mucosal immune memory.** BALB/c mice were vaccinated orally with the recombinant ST-10E8, empty vector ST or PBS for three times, and serum specific IgG and mucosal IgA titers were measured at day 14 after the final vaccination. Immunization with ST-10E8 induced a high level of serum 10E8-specific IgG response with an endpoint antibody titer of 1:1,859 (Fig. 2a). The 10E8 specific mucosal secretory IgA (sIgA) was also observed in the intestinal washes (Fig. 2b). Two of the five serum samples tested showed strong neutralizing activities against HIV-1 SF162 virus (NP value more than 50%) (Fig. 2c). No 10E8 peptide specific serum IgG, mucosal sIgA or neutralizing antibody response was detected in mice immunized with the ST vector or PBS.

---

**Figures:**

1. **Fig. 1.** A schematic diagram of gene replacement and fimbriae expression. (a) Fimbriae expression in live attenuated Salmonella typhimurium ST-10E8. (b) CR binding assay. (c,d) Survival curves of BALB/c mice infected with ST or ST-10E8. (e,f) Bacterial loads of ST or ST-10E8 (referred to as ST hereafter) in the spleens and Peyer's patches of BALB/c mice infected with 1 × 109 CFU of ST-10E8 or ST at day 3, 7, and 14.

---

**Tables:**

| Vaccine   | Serum IgG | Mucosal sIgA |
|-----------|-----------|---------------|
| ST-10E8   | 1:1,859   | 1:1000        |
| ST         | 1:100     | 1:100         |
| PBS        | 1:100     | 1:100         |

---

**References:**

1. [Innate immunity and vaccine development](#).
2. [HIV-1 infection and immunity](#).
3. [Epitope-specific neutralizing antibodies](#).
4. [Live attenuated vaccines](#).
5. [Delivery systems for HIV-1 vaccines](#).
6. [Clinical trials of HIV-1 vaccines](#).
7. [Future perspectives](#).
Considering that the Salmonella vector itself contains multiple immunogens that might disturb the immunogenicity of heterologous antigens, we conducted additional homologous peptide boosting to drive the immune responses toward the 10E8 epitope more effectively and specifically. We performed two 10E8 peptide boosts and found that the ST-10E8 prime-10E8 boost regime gave approximate 2-fold increase (endpoint antibody titers of 1:3,273) of serum IgG titer than ST-10E8 immunization alone (Fig. 2a), significant improvement of mucosal sIgA responses in intestinal washes (Fig. 2b) and neutralizing antibody responses in four of five sera (Fig. 2c).

Following the 10E8 peptide boosts, the ST primed mice (ST/10E8) did not produce significant 10E8 specific IgG, sIgA or neutralizing antibody response, consistent with previous findings that HIV-1 BNAb epitope peptide alone hardly induced effective specific antibody responses. These results suggest that ST-10E8 prime stimulated differentiation of specific T and B cells and promoted the formation of immune memory responses, contributing to rapid recall antibody responses following 10E8 peptide boosts.
ST-10E8 stimulated differentiation of specific antibody-secreting plasma cells in bone marrow. We next measured the 10E8 epitope-specific antibody-secreting cells (ASCs) and total IgG ASCs in bone marrow after the final 10E8 peptide boost by B cell ELISpot assays. We found that ST-10E8/10E8 immunization induced significantly more specific ASCs and total IgG ASCs than PBS control group (Fig. 2d–f). The number of specific ASCs was positively correlated with the endpoint titer of specific serum IgG (Fig. 2g). Consistent with the results of specific antibody responses found in the above assays, ST/10E8 immunized mice did not generate obvious specific antibody-secreting plasma cells. Moreover, prime immunization with ST strains (ST-10E8 or ST) resulted in higher frequencies of total IgG ASCs than that with PBS, indicating that ST vector itself could facilitate B cell differentiation and would provide Thelper subsets or cytokine microenvironment helpful for specific antibody development.

Attenuated ST immunization induced more serum IgG antibody and directed the immune responses towards Th1 bias. Consistent with the results of total IgG ASCs in bone marrow, ST-10E8/10E8 and ST/10E8 immunized mice produced similar levels of serum total IgG antibodies, significantly higher than that in PBS control (Fig. 3a), suggesting that ST vector-specific IgGs were induced in the sera of the immunized
mice. Correlation analyses showed that the serum total IgG concentration was positively associated with the total IgG ASC in bone marrow and the specific antibody titer in serum (Fig. 3b,c). Both of the ST-10E8/10E8 and ST/10E8 groups also showed higher levels of serum IgG1, IgG2a and IgG2b subclasses than PBS group (Fig. 3d). No difference was observed in IgG3 levels among the three groups (Fig. 3d). Moreover, ST-10E8/10E8 and ST/10E8 immunization directed the immunity to Th1 bias as demonstrated by the ratio of IgG2a/IgG1 (Fig. 3e). Vaccination stimulation can change local cytokine microenvironment that will in turn influence the differentiation of T helpers, whose appropriate reaction is essential to the development and function of B cells. Therefore, we next assessed the cytokine profile in immunized mouse sera. We found that the sera of the ST-10E8/10E8 and ST/10E8 immunized mice contained significantly higher levels of both Th1 cytokines (IL-10, IFN-γ, and TNF-α) and Th2 cytokines (IL-4, IL-6, IL-21) than those of the PBS control mice (Fig. 3f), indicating that immunization with these STs induced mixed Th1 and Th2 immune responses and that cellular immunity and cytokine secretion induced by attenuated STs would further promote B cell differentiation and antibody production.

Immunization with attenuated ST induced higher levels of splenocyte proliferation and B cell differentiation. After the final boost, spleens and Peyer’s patches were isolated. As expected, we found that ST-10E8/10E8 and ST/10E8 immunized mice had much larger spleen weight indexes, as presented by the rate of spleen weight to mouse body weight, than PBS immunized mice (Fig. 4a,b), indicating that STs immunization induced significant proliferation of the immunized splenocytes. Then, we evaluated the 10E8 peptide specific proliferation under stimulation with the 10E8 peptide by CCK-8 assays, and found that the lymphocytes from ST-10E8/10E8 group showed significantly higher proliferative activity than that from ST/10E8 group, with proliferation indexes (PIs) of 1.46 and 1.15, respectively. The lymphocytes from PBS group showed no obvious proliferation activity against 10E8 peptide (PI = 1.02) (Fig. 4c). We also found that the spleen weight index was positively correlated with the splenocyte proliferation index (Fig. 4d), and both the spleen weight index and splenocyte proliferation index were positively correlated with the serum total IgG concentration and the total IgG ASC in bone marrow (Fig. 4e,f). These results suggested that immunization with recombinant Salmonella ST-10E8 stimulated proliferation and expansion of 10E8 specific lymphocytes as well as the formation of specific memory lymphocytes, which were rapidly activated by 10E8 peptide boosts, and that the attenuated ST vector induced non-10E8 specific splenocyte proliferation.

We next wanted to know whether immunization with these STs could effectively induce B cell differentiation. Consistent with the above findings, mice immunized with ST-10E8/10E8 or ST/10E8 immunized mice had much larger spleen weight indexes, as presented by the rate of spleen weight to mouse body weight, than PBS immunized mice (Fig. 4a,b), indicating that STs immunization induced significant proliferation of the immunized splenocytes. Then, we evaluated the 10E8 peptide specific proliferation under stimulation with the 10E8 peptide by CCK-8 assays, and found that the lymphocytes from ST-10E8/10E8 group showed significantly higher proliferative activity than that from ST/10E8 group, with proliferation indexes (PIs) of 1.46 and 1.15, respectively. The lymphocytes from PBS group showed no obvious proliferation activity against 10E8 peptide (PI = 1.02) (Fig. 4c). We also found that the spleen weight index was positively correlated with the splenocyte proliferation index (Fig. 4d), and both the spleen weight index and splenocyte proliferation index were positively correlated with the serum total IgG concentration and the total IgG ASC in bone marrow (Fig. 4e,f). These results suggested that immunization with recombinant Salmonella ST-10E8 stimulated proliferation and expansion of 10E8 specific lymphocytes as well as the formation of specific memory lymphocytes, which were rapidly activated by 10E8 peptide boosts, and that the attenuated ST vector induced non-10E8 specific splenocyte proliferation.

We next wanted to know whether immunization with these STs could effectively induce B cell differentiation. Consistent with the above findings, mice immunized with ST-10E8/10E8 or ST/10E8 developed higher frequencies of GC B (Fas-GL-7+CD19+CD3-; Fig. 5a–c), memory B (CD38+CD19+CD3-; Fig. 5d–f) in the spleen and Peyer’s patches, and plasma cells (CD138+CD19+CD3-; Fig. 5g,h) in bone marrow, than PBS immunized mice. The frequencies of these B subsets were slightly higher in ST-10E8/10E8 group than those in ST/10E8 groups (P > 0.05). The frequencies of the GC B cells in Peyer’s patches and the plasma cells in bone marrow were
positively correlated with the serum total IgG concentration and the total IgG ASC in bone marrow (Fig. 5i–l). These results suggested that the attenuated STs prime could effectively stimulate germinal center formation and plasma cell development, and 10E8 boost might trigger 10E8 specific B cell differentiation.

Discussion

It is well accepted that the elicitation of neutralizing Ab responses and induction of effective B cell responses play a central role in preventing HIV-1 infection31,32. Thus, an ideal vaccine candidate coupled with an appropriate vaccination regimen is needed desperately. However, various vaccine strategies for such a goal have all failed to date. In this study, we constructed a live attenuated *Salmonella*-vectored HIV-1 vaccine candidate that effectively expressed heterologous HIV-1 10E8 epitopes on bacterial fimbriae. We found that by using a recombinant bacterial ST-10E8 prime plus 10E8 peptide boost immunization regimen, this oral recombinant live bacterial vaccine could induce 10E8 epitope-specific antibody responses in peripheral and mucosal sites, and stimulate effective B cell differentiation.

HIV-1 Env is considered the primary target of neutralizing antibodies and comprises several well-defined regions that could be potential immunogens for vaccine development. The MPER of HIV-1 gp41 protein that is characterized as highly conserved among diverse HIV strains consists of several distinct short linear antigenic regions targeted by several BNAbs. However, when it comes to vaccine strategy, in order to generate effective Ab responses, the MPER antigens should be constructed and delivered in an appropriate way to improve the immunogenicity of the antigenic component33,34. Here, we employed *Salmonella* as the antigen delivery platform to present HIV-1 10E8 epitopes on its fimbriae. Our results showed that ST-10E8 could induce specific serum IgG and mucosal sIgA responses, and that *Salmonella* fimbriae display strategy could enhance the immunogenicity of the immunogens. Consistently, previous studies have reported that *Salmonella*-vectored DNA vaccine could significantly augment the systemic and mucosal antibody responses23,28,29. In addition, these findings are also consistent with our earlier work, in which we constructed *Salmonella* fimbriae based tumor vaccines and found that such a strategy can enhance the immunogenicity of tumor associated antigens and reduced the growth rate of the tumor cells35.

The “adjuvant effect” of *Salmonella* vectors in the enhancement of heterologous antigen immunogenicity seems to be derived from its capacity to modulate innate immune responses through the activation of TLR4 pathway36,37. Additionally, it has been reported that the flagellum TLR-mediated pathway is necessary for antibody responses46. But the mechanism for *Salmonella* fimbriae-mediated immunity enhancement is still unknown. Our results showed that immunization with attenuated *S. typhimurium* 14028-3b promoted production and secretion of several Th1 and Th2 type cytokines in serum, and stimulated B cell differentiation into GC B cells, memory B cells and plasma cells, indicating the immune activation effects of the *Salmonella* vector. Moreover, ST immunization seemed to direct the immune responses towards Th1 bias, consistent with previous findings36,60.

Granted that *Salmonella*-vectored immunogens came up with improved immunogenicity, the data in our experiments show that such improvement is not as profound as MPER vaccines in some previous reports41,42. Taken together, it indicates that immunological responses against the pathogenic bacterial vector certainly exist and that additional solutions are required to modulate the immune systems to target heterologous antigens specifically.

Figure 4. Spleen weight index and splenocyte proliferation activity. (a,b) The spleens from immunized mice were isolated and weighted, and spleen weight index were calculated as organ weight (milligram, mg) per gram (g) of mouse body weight. (c) The proliferation activity of splenic lymphocytes were measured under stimulation with 5μg/ml 10E8 peptide or medium alone by CCK-8 assays. The proliferation index was expressed as the OD450 ratio of the peptide stimulation wells to the corresponding medium control wells. The correlations between the spleen weight index and the proliferation index (d), between the spleen weight index and serum total IgG (e), total IgG ASC (f), and between the proliferation index and serum total IgG (g), total IgG ASC (h) were shown. R, correlation coefficient. Data shown as mean ± SD of 5 mice in each group.
Figure 5. B cell subset differentiation induced by attenuated *Salmonella* immunization. (a–h) Contour plots and statistical graphs of GC B cells (Fas⁺GL-7⁺CD19⁺CD3⁻) (a–c), memory B cells (CD38⁺CD19⁺CD3⁻) (d–f) in spleen and Peyer's patches, and plasma cells (CD138⁺CD19⁻CD3⁻) in bone marrow (g,h) at day 14 after final 10E8 peptide boost were shown. The correlations between the GC B frequency in Peyer's patches and serum total IgG (i), total IgG ASC (j), and between plasma cell frequency in bone marrow (BM) and serum total IgG (k), total IgG ASC (l) were shown. R, correlation coefficient. Data shown as mean ± SD of 5 mice in each group.
In an ongoing study, we immunized mice with ST-10E8 up to five times with a three-week interval based on the bacterial clearance kinetics. The preliminary results showed that the serum 10E8 specific Ab reached the peak level at day 14 after 3rd immunization, and 4th and 5th immunizations did not yield any further improvement of specific Ab responses (data not shown). These findings suggest that more than three times of ST-10E8 immunization might lead to immune tolerance to the live Salmonella vector. Thus, in the present work, we determined to adopt 10E8 peptide boosts rather than repeat Salmonella immunizations. We found that boost vaccinations could enhance the Ab responses induced by ST-10E8 vaccination prime.

Moreover, further evaluation of plasma cell responses involving the plasma cell subsets in bone marrow and their antibody secreting function showed that the ST-10E8/10E8 regimen effectively drove B cells to focus on epitope-specific immune responses. Consistently, our analysis of the germinal center B cell responses occurring in spleens and Peyer’s patches supported these findings. The ST-10E8/10E8 vaccination regimen stimulated effective GC B cell responses, which is indispensable for later plasma B cell responses43,44.

To study the primary mechanisms underlying the B cell immune response stimulated by such vaccination strategy, we further evaluated serum cytokine profiles following last boost. We found that the ST-10E8/10E8 vaccination regimen stimulated mice to generate high levels of Th1 (IL-10, IFN-γ and TNF-α) cytokines and Th2 cytokines (IL-4, IL-6 and IL-21), with the Th1 cytokines being predominant. Additionally, the assessment revealed that the Th1 cytokine IL-21 was also effectively generated within the experimental group, which is consistent with the previous results regarding B cell responses following vaccination where IL-21 plays essential role in the formation and maintenance of germinal center activities45.

Overall, immunogenicity of the HIV-1 10E8 epitope was enhanced in our study by presenting the epitope peptide with the Salmonella fimbriae. The ST-10E8 prime and 10E8 epitope peptide boost vaccination regimen generated effective systemic and mucosal immune Ab responses to HIV-1 10E8 epitope. Furthermore, this regimen could drive more antibody secreting plasma cells specific to 10E8 epitope, which was supported by the analyses of germinal B cell responses and the assessment of serum cytokine profiles.

Methods

Bacterial strain and plasmid. The ST-14028-3b aroA− strain (referred to as ST) was derived from Salmonella typhimurium 14028-3b and attenuated by deletion of AroA-coding gene. The plasmid pHSG415 contains a kanamycin-resistant gene for positive colony selection46 and was used in the construction of 10E8 epitope-expressing recombinant strain ST-10E8. The ST vector and the recombinant ST-10E8 strains were cultured in Luria Bertani (LB) medium at 37 °C.

Construction of the recombinant ST-10E8 and AgfA deficient ST strains. The chi-meric gene segment, agfA::10E8, was amplified by overlapping PCR as described previously47,48. Briefly, the upstream and downstream agfA segments containing the 10E8 insert were amplified by using primers agfA-for (5′-GCGAATTCCAGCTTGTAGTCGACAAAGCATGCATAT-3′) and 10E8-2 (5′-ACCGGATTTTATATACCACAGCCAGTTGTGTTGTTGTTGCAACAAATTGG ATCCATTATCGCACCTTGCTACATCG-3′), and the primers agfA-rev (5′-AGACGGAAGCTCTGGTTTTAATGACCTGACGGGATCACC-3′) and 10E8-1 (5′-GGATCAATTGGTTTGGACA TAACAAAATGTGTTGATATATATCAATCGTGACCCGTGGCAGCGTAAAGCTGACACTCCGAT-3′), respectively. Then, with the resulting gene segments as the PCR template, the chimeric gene segment, agfA::10E8, was amplified by using the primers agfA-for and agfA-rev. The final PCR product was inserted between the sites of EcoR I and Hind III of the plasmid pHSG415. After confirmation by sequencing, the recombinant plasmid pHSG415-agfA::10E8 was transformed into ST strain by electroporation, and the recombinant ST-10E8 strain was obtained by replacement of corresponding wild-type agfA gene segment in the chromosome with the chimeric agfA::10E8 under selective pressure of ampicillin at 42 °C, as described previously49. The AgfA-deficient ST strain (ST-ΔAgfA) was constructed by the same procedure as described previously49.

Western bolt analysis of fusion protein agfA-10E8. ST, ST-10E8 or ST-ΔAgfA were cultured on LB-agar plates, harvested and resuspended in Tris buffer (10 mM Tris, pH 7.5). The cell suspension was mixed with 6 × sample loading buffer (350 mM Tris–HCl pH 6.8, 3% glycerol, 10% SDS, 6% (–mercaptoethanol) and then boiled for 10 min. The insoluble components containing thin aggregate fimbrinae AgfA were collected by centrifugation, and then treated with 90% formic acid for 45 s49. The formic acid was removed by Speed Vac Concentrator at 60 °C for 45 min50,51. The resultant protein samples were separated by SDS-PAGE, transferred to PVDF membrane, and detected using polyclonal rabbit anti-AgfA sera and monoclonal antibodies 10E8, 4E10, respectively. The mAbs 4E10 and 10E8 were obtained from the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH.

Congo red binding assay. The amounts of Congo red (CR) bound by ST-10E8 and ST were determined by CR binding assay, as described previously47,48. Bacterial cells were cultured on LB agar plates supplemented with 100 μg/ml CR for 24 h. The cells were scrapped from the plate and resuspended to the A600 of 1 (1 × 108 CFU/ml) in 10 mM Tris-HCl (pH 7.0). The suspension was equilibrated for 1 h at room temperature (RT), and then 1 ml aliquots were transferred into tubes containing 50 μl 30% PEG8000. The bacterial cells were removed from the tube by centrifugation at 15,000 × g for 5 min. The amounts of CR released into the supernatants were measured by reading optical density (OD) value at 480 nm.

Mice, oral immunization and sample collection. Female BALB/c mice (8–10-week old) were purchased from Vital River Laboratories (Beijing, China) and housed in the Animal Laboratory of Harbin Medical University. The methods of animal experiments were carried out in strict accordance with the recommendations.
in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All experimental protocols were approved by Animal Care and Use Committee of Harbin Medical University (HMUIRB20150024).

In order to measure the LD50 of ST strains, 10 mice per group were orally administered with ST-10E8 or ST ranging from $1 \times 10^1$ to $1 \times 10^4$ CFU. The survival rate of infected mice was monitored weekly for a 28-day period. In order to examine the organ distribution of ST strains, 12 mice per group were infected orally with $1 \times 10^8$ CFU of ST-10E8 or ST. At days 3, 9, 16, 30 post infection, the spleens and Payer’s patches were isolated to determine the bacterial loads by plating the organ homogenates on LB-agar plates as previously described.

For immunogenicity evaluation, 5 mice per group were inoculated orally with $1 \times 10^8$ CFU of ST-10E8, ST or PBS at weeks 0, 3 and 6. Blood samples were collected via the tail vein at day 14 after the third vaccination. All ST-10E8 or ST primed mice were boosted intraperitoneally with $20 \mu g$ 10E8 peptide emulsified in Freund's adjuvant at weeks 9 and 12. The PBS-primed mice were boosted with the adjuvant alone. The sera, spleens, Payer’s patches and bone marrows were collected at day 14 after the second 10E8 peptide boost. A 10-cm intestinal segment in duodenum region from each mouse was also collected, cut into 1-cm length pieces and washed thoroughly with 1 ml PBS. The intestinal washes were used for mucosal IgA detection.

**Measurement of 10E8 peptide specific binding antibody responses.** 10E8 epitope-specific binding antibodies in serum and intestinal washes were analyzed by Enzyme-linked immunosorbent assay (ELISA). Briefly, 96-well plates were coated with purified synthetic 10E8 epitope peptide (NWFDITNWLWYIK) at the final concentration of 0.5 $\mu g/ml$, and incubated at 4°C for 12 h. The plates were washed three times with PBS containing 0.05% Tween-20 (PBST) and then were blocked with the blocking buffer (2% skim milk in PBST) at 37°C for 1 h.

After washings, intestinal washes or serially diluted mouse sera were added and incubated at 37°C for 1 h. After washings, horseradish peroxidase (HRP)-conjugated goat anti-mouse IgA or IgG (ZSGB-BIO, Beijing, China) was added and incubated at 37°C for 1 h. And then, 3,3’,5,5’-tetramethyl benzidine (TMB) substrate was added and incubated at RT for 30 min. The reaction was stopped by addition of 50$\mu l$ of 2 M H2SO4 solution. The absorbance value at 450 nm (OD450) was read using ELISA reader (Bio-Rad, California, USA).

**Detection of anti-HIV-1 neutralizing activity of sera from immunized mice.** Neutralization assays on HIV-1 SF162 Env pseudovirus were performed in TZM-bl cells as previously described. Briefly, mouse sera were heat-inactivated at 56°C for 1 h prior to the assay, and 1:10 diluted in DMEM containing 10% heat-inactivated fetal bovine serum. A one hundred 50% tissue culture infective dose (TCID50) of SF162 Env pseudovirus (25$\mu l$) and the diluted serum (25$\mu l$) were mixed, added to a 96-well plate in duplicate and incubated at 37°C for 1 h.

Then, 50$\mu l$ TZM-bl cell suspension containing $1 \times 10^4$ cells was added to each well. After incubation at 37°C for 60 h, 100$\mu l$ of Bright-Glo Luciferase assay System (Promega, Wisconsin, USA) was added to each well and incubated at RT for 5 min. The relative luminescence unit (RLU) in each well was read with a ModulusII microplate multimode reader (Turner BioSystems, California, USA). The neutralization activity of the mouse sera was expressed as neutralization percentage (NP) calculated as the percentage of reduction in RLU values in wells containing pseudovirus and serum relative to the RLU values in wells containing pseudovirus alone. The TZM-bl cell line was obtained from the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH.

**Analysis of antibody secreting cells in bone marrow.** The 10E8 peptide specific and total IgG antibody secreting cells (ASCs) were detected by B-ELISPOT assays using the ELISpotPLUS for Mouse IgG kit (Mabtech, Nacka Strand, Sweden) as described previously. Briefly, the 96-well plate was pre-wetted with ethanol, and then added with anti-mouse IgG antibody (15$\mu g/ml$) and incubated overnight at 4°C. After washes with PBS, the plate was blocked with RPMI1640 medium containing 10% fetal calf serum (FCS) for 30 min at RT. After removal of blocking buffer, 1 $\times 10^5$ or 1 $\times 10^6$ bone marrow cells per well, for total IgG ASCs or for specific IgG ASCs detection, respectively, were added and incubated at 37°C, 5% CO2 for 22 h. After removal of the cells and washes, the plates were further incubated with anti-IgG-biotin or biotin-labeled 10E8 peptide. Following additional incubation with Streptavidin-ALP (1:1,000) at RT for 1 h, the plates were developed with BCIP/NBT solution. The numbers of the cell spots were counted using an ELISpot reader (Sage Creation Science, Beijing, China).

**Analysis of serum IgG subclasses and the Th bias of immunity induced by attenuated STs.** Serum total IgG was quantitatively measured by using the Mouse IgG total ELISA Ready-SET-Go Kit (eBioscience, San Diego, California, USA) following the manufacturer’s instructions. Briefly, the anti-IgG antibodies were added onto 96-well plates and incubated overnight at 4°C. After washing with PBST and blocking, the serum samples (1:10,000) or 2-fold serially diluted IgG standards, and the detection antibodies were incubated at RT for 3 h. Then, the substrate solutions were added and incubated at RT for 15 min. The stopping of reactions and the reading of OD450 values were performed as described above.

IgG subclass concentrations in mouse sera were quantitatively determined by using Mouse IgG Subclass ELISA kits (Enzyme-linked Biotechnology Co., Ltd., Shanghai, China). Briefly, serum samples from immunized mice were diluted and added into the 96-well plates that were pre-coated with anti-mouse IgG1, IgG2a, IgG2b or IgG3 antibodies, and then incubated at 37°C for 30 min. After five times of washes, HRP-conjugated anti-mouse IgG1, IgG2a, IgG2b or IgG3 antibodies were added. After incubation and washes, the substrate solution was added into each well for color development. The stopping of reactions and the reading of OD450 values were performed as described above. The concentrations of IgG subclasses in mouse sera were calculated according to the standard curves, which were constructed by using the standard mouse IgG1, IgG2a, IgG2b or IgG3 proteins.

**Measurement of serum cytokine profiles.** Secretory levels of cytokines IL-4, IL-6, IL-10, IL-21, IFN-γ and TNF-α in the mouse sera were quantitatively determined using the ELISA kits (BOSTER, Wuhan, China) according to the manufacturer’s instructions. Briefly, sera from the immunized mice (1:10 dilution) were added to the cytokine-specific antibody coated 96-well plates and incubated at 37°C for 1.5 h. After removal of unbound
serum proteins, biotin-labeled cytokine-specific detection antibody was added and incubated at 37 °C for 1 h. The plates were washed three times and then were incubated with streptavidin-HRP for 30 min. After washes, the TMB substrate solution was added, and color reaction was developed. The stopping of reactions and the reading of OD450 values were performed as described above. Cytokine concentrations were calculated by using the standard curves derived from the recombinant cytokine standards.

**Antigen-specific splenocyte proliferation assay.** Splenocytes from immunized mice were harvested and lymphocytes were isolated. The lymphocytes (5 × 10^6 cells/well) were incubated with 5 μg/ml of 10E8 or medium alone (unstimulated) in duplicate for 72 h at 37 °C. The proliferation activity was examined by Cell Counting Kit-8 (Dojindo Molecular Technologies, Tokyo, Japan). The proliferation index was calculated as the ratio of OD450 values in stimulated cells to those in the corresponding unstimulated control.

**Flow cytometry analyses.** Suspensions of single lymphocytes from spleens and Payer’s patches were prepared and stained with antibodies as follows: anti-CD3-Pacific blue, anti-CD19-PE/Cy7, anti-CD138-biotin, anti-Fas-PE/CF594, anti-GL7-FITC and Streptavidin-PE from BD Biosciences (California, USA). The lymphocytes from bone marrows were isolated and stained with anti-CD3-Pacific blue, anti-CD19-PE/Cy7, and anti-CD138-biotin. Flow cytometry data were acquired by the flow cytometer (CantoII; BD Biosciences) and analyzed with FlowJo software (version 10; Tree Star Inc, Oregon, USA).

**Statistics**

Statistical analyses were performed by using GraphPad Prism version 5.0 (GraphPad Software, California, USA). The data were expressed as mean ± SD. A students’ t-test (two-tailed) was used to compare the means between any two groups. Pearson’s correlation coefficient was employed to determine linear relations between two parameters. P values less than 0.05 were considered statistically significant.

**References**

1. Burton, D. R. et al. A Blueprint for HIV Vaccine Discovery. *Cell host & Microbe* **12**, 396–407 (2012).
2. Haynes, B. F. New approaches to HIV vaccine development. *Current opinion in immunology* **35**, 39–47 (2015).
3. Kim, J. H., Rekiks-Nigam, S., Excler, J. L. & Michael, N. L. HIV vaccines: lessons learned and the way forward. *Current opinion in HIV and AIDS* **5**, 428–434 (2010).
4. Rekiks-Nigam, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. *The New England journal of medicine* **361**, 2209–2220 (2009).
5. Lycke, N. Recent progress in mucosal vaccine development: potential and limitations. *Nature reviews. Immunology* **12**, 592–605 (2012).
6. Belyakov, I. M. & Ahlers, J. D. Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development. *Current topics in microbiology and immunology* **354**, 157–179 (2012).
7. Woodrow, K. A., Bennett, K. M. & Lo, D. D. Mucosal vaccine design and delivery. *Annual review of biomedical engineering* **14**, 17–46 (2012).
8. Cicala, C., Arthos, J. & Fauci, A. S. HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV. *Journal of translational medicine* **9** Suppl 1, S2 (2011).
9. McKinnon, L. R. & Kaul, R. Quality and quantity: mucosal CD4+ T cells and HIV susceptibility. *Current opinion in HIV and AIDS* **7**, 195–202 (2012).
10. Kwong, P. D., Mascola, J. R. & Nabel, G. J. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. *Cold Spring Harbor perspectives in medicine* **1**, a007278 (2011).
11. Gray, E. S. et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. *Journal of virology* **85**, 4828–4840 (2011).
12. Haber, P. et al. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. *AIDS* **28**, 163–169 (2014).
13. West, A. P., Jr. et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. *Cell* **156**, 633–648 (2014).
14. Klein, F. et al. Antibodies in HIV-1 vaccine development and therapy. *Science* **341**, 1199–1204 (2013).
15. Mascola, J. R. & Haynes, B. F. HIV-1 neutralizing antibodies: understanding nature's pathways. *Immunological reviews* **254**, 225–244 (2013).
16. Salzwedel, K., West, J. T. & Hunter, E. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. *Journal of virology* **73**, 2469–2480 (1999).
17. Scherer, E. M., Leaman, D. P., Zwick, M. B., McMichael, A. J. & Burton, D. R. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. *Proceedings of the National Academy of Sciences of the United States of America* **107**, 1529–1534 (2010).
18. Ohe, G. et al. Elicitation of structure-specific antibodies by epitope scaffolds. *Proceedings of the National Academy of Sciences of the United States of America* **107**, 17880–17887 (2010).
19. Guenaga, J. et al. Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. *PloS one* **6**, e10074 (2011).
20. Wahome, N. et al. Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine. *Chemical biology & drug design* **80**, 349–357 (2012).
21. Yi, G. et al. Chimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responses. *PloS one* **8**, e72205 (2013).
22. Pawelek, J. M. et al. Salmonella pathogenicity island-2 and anticancer activity in mice. *Cancer gene therapy* **9**, 813–818 (2002).
23. Kong, W., Brovold, M., Koeneman, B. A., Clark-Curtiss, J. & Curtiss, R., 3rd. Turning self-destructing Salmonella into a universal DNA vaccine delivery platform. *Proceedings of the National Academy of Sciences of the United States of America* **109**, 19414–19419 (2012).
24. Jawale, C. V. & Lee, J. H. Salmonella enterica serovar enteritidis ghosts carrying the Escherichia coli heat-labile enterotoxin B subunit are capable of inducing enhanced protective immune responses. *Clinical and vaccine immunology: CVI* **21**, 799–807 (2014).
25. Kong, W., Clark-Curtiss, J. & Curtiss, R., 3rd. Utilizing Salmonella for antigen delivery: the aims and benefits of bacterial delivered vaccination. *Expert review of vaccines* **12**, 345–347 (2013).
26. Roland, K. L. & Brenneman, K. E. Salmonella as a vaccine delivery vehicle. *Expert review of vaccines* **12**, 1033–1045 (2013).
27. Haraga, A., Ohlson, M. B. & Miller, S. I. Salmonellae interplay with host cells. *Nature reviews. Microbiology* **6**, 53–66 (2008).
28. Yu, X. et al. Attenuated Salmonella typhimurium delivering DNA vaccine encoding duck enteritis virus UL24 induced systemic and mucosal immune responses and conferred good protection against challenge. *Veterinary research* **43**, S6 (2012).
29. Wen, J. et al. Salmonella typhi Ty21a bacterial ghost vector augments HIV-1 gp140 DNA vaccine-induced peripheral and mucosal antibody responses via TLR4 pathway. *Vaccine* 30, 5733–5739 (2012).

30. Wang, Y. J. et al. Two oral HBs vaccines delivered by live attenuated *Salmonella*: both eliciting effective anti-tumor immunity. *Cancer letters* 263, 67–76 (2008).

31. Sattentau, Q. J. Immogenon design to focus the B-cell repertoire. *Current opinion in HIV and AIDS* 9, 217–223 (2014).

32. Cohen, K., Allfeld, M., Ahler, G. & Stamatatos, L. Early preservation of CACR5+ PD-1+ helper T cells and B-cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection. *Journal of virology* 88, 13310–13321 (2014).

33. Burton, D. R. et al. HIV vaccine design and the neutralizing antibody problem. *Nature immunology* 5, 233–236 (2004).

34. Girard, M. P., Osmanov, S., Assousou, O. M. & Kienny, M. P. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. *Vaccine* 29, 6191–6218 (2011).

35. Meng, J. Z. et al. Oral vaccination with attenuated *Salmonella* enterica strains encoding T-cell epitopes from tumor antigen NY-ESO-1 induces specific cytotoxic T-lymphocyte responses. *Clinical and vaccine immunology* CVT 17, 889–894 (2010).

36. Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. *Cell* 140, 805–820 (2010).

37. Treanor, J. I. et al. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. *Vaccine* 28, 8268–8274 (2010).

38. Oh, J. Z. et al. TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination. *Immunity* 41, 478–492 (2014).

39. Porta, A., Morello, S., Granata, L., Iannone, R. & Maresca, B. Insertion of a 59 amino acid peptide in *Salmonella* Typhimurium membrane results in loss of virulence in mice. *The FEBRS journal* 281, 5043–5053 (2014).

40. Patthangey, L., Kohiler, J. J., Isoda, R. & Brown, T. A. Effect of expression level on immune responses to recombinant oral *Salmonella* enterica serovar Typhimurium vaccines. *Vaccine* 27, 2707–2711 (2009).

41. Yu, Y., Tong, F., Li, Y., Lu, Z. & Chen, Y. 10E8-like neutralizing antibodies against HIV-1 induced using a precisely designed conformational peptide as a vaccine prime. *Science China. Life sciences* 57, 117–127 (2014).

42. Jain, S., Patrick, A. J. & Rosenthal, K. L. Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen. *Vaccine* 28, 7070–7080 (2010).

43. Tangye, S. G. Staying alive: regulation of plasma cell survival. *Trends in immunology* 32, 595–602 (2011).

44. Eibel, H., Kraus, H., Sic, H., Kienzler, A. K. & Rizzi, M. B cell biology: an overview. *Current allergy and asthma reports* 14, 434 (2014).

45. Eibel, H., Kraus, H., Sic, H., Kienzler, A. K. & Rizzi, M. B cell biology: an overview. *Current allergy and asthma reports* 14, 434 (2014).

46. White, A. P. et al. High efficiency gene replacement in *Salmonella* enteritidis: chimeric fimbrins containing a T-cell epitope from *Leishmania major*. *Vaccine* 17, 2130–2161 (1999).

47. White, A. P., Collinson, S. K., Banser, P. A., Dolhaine, D. J. & Kay, W. W. *Salmonella* enteritidis fimbrinae displaying a heterologous epitope reveal a uniquely flexible structure and assembly mechanism. *Journal of molecular biology* 296, 361–372 (2000).

48. White, A. P. et al. An efficient system for markerless gene replacement applicable in a wide variety of enterobacterial species. *Canadian journal of microbiology* 53, 56–62 (2007).

49. Huang, H. et al. *Salmonella* expressing a T-cell epitope from Sendai virus are able to induce anti-infection immunity. *Journal of medical microbiology* 58, 1236–1242 (2009).

50. Collinson, S. K. et al. Thin, aggregative fimbrinae mediate binding of *Salmonella* enteritidis to fibronectin. *Journal of bacteriology* 175, 12–18 (1993).

51. Collinson, S. K., Emody, L., Muller, K. H., Trust, T. J. & Kay, W. W. Purification and characterization of thin, aggregative fimbrinae from *Salmonella* enteritidis. *Journal of bacteriology* 173, 4773–4781 (1991).

52. Barthele, M. et al. Pretreatment of mice with streptomycin provides a *Salmonella* enterica serovar Typhimurium colitis model that allows analysis of both pathogen and host. *Infection and immunity* 71, 2839–2858 (2013).

53. Li, Q.-H., Chen, W.-J., Liu, S.-L. & Ling, H. Toxicity and biological distribution of attenuated *Salmonella* typhimurium bearing HIV-1 2F5 epitope in BALB/c mice. *Chin J Public Health* 24, 1004–1005 (2008).

54. Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. *J Virol* 89, 5733–5739 (2012).

55. Erickson, L. D., Lin, L. L., Duan, B., Morel, L. & Noelle, R. J. A genetic lesion that arrests plasma cell homing to the bone marrow. *Proceedings of the National Academy of Sciences of the United States of America* 100, 12905–12910 (2003).

Acknowledgements

This study was supported by grants from Harbin Science and Technology Bureau (2012RFXXS035), Natural Science Foundation of Heilongjiang Province (H201383), Health and Family Planning Commission of Heilongjiang Province (2013140), and Innovative and Entrepreneurial Training Plan for College Students of Heilongjiang Province (20150226017), and National Natural Science Foundation of China (81271786, 81030029).

Author Contributions

S.-L.L. and Q.-H.L. designed the research; Q.-H.L., G.J., J.-Y.W., H.-N.L., H.-D.L. and X.-Y.C. performed research; S.-L.L., Q.-H.L., G.J. and J.-Y.W. analyzed data; S.-L.L. and F.-X.W. contributed reagents; S.-L.L., Q.-H.L., G.J. and J.-Y.W. wrote the paper. All authors reviewed the manuscript.

Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Li, Q.-H. et al. Live attenuated *Salmonella* displaying HIV-1 10E8 epitope on fimbrae: systemic and mucosal immune responses in BALB/c mice by mucosal administration. *Sci. Rep.* 6, 29556; doi: 10.1038/srep29556 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/